Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Stock Hits Price Target Forecast with 17.79% Profit - QuantWave Analysis

May 03, 2023
ELI LILLY AND COMPANY stock has successfully reached the price target forecast set by QuantWave on December 12, 2022. The forecast indicated a long direction with the price at 359.95 USD at the time of the signal. On May 3, 2023, the stock reached the predicted price of 423.98 USD, resulting in a profit of 17.79%.

This achievement highlights the accuracy and effectiveness of QuantWave's forecasting capabilities in predicting stock movements. The market analysis indicates that ELI LILLY AND COMPANY experienced positive growth leading to the price target being met. Factors such as strong financial performance, positive industry trends, and possible developments in the healthcare sector may have contributed to the stock's movement.

QuantWave stands out as an automated forecasting platform that provides users with predictions for various stocks, offering profitable opportunities based on data-driven analysis. Investors can benefit from the platform's insights to make informed decisions and potentially generate significant returns. For a deeper understanding of QuantWave's investment strategy, individuals are encouraged to explore the educational resources provided by QuantSchool, which offers a professional investment framework for consistent income generation using the QuantWave forecasting system.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....

LLYMarch 22, 2025Eli Lilly and Company LLY: Leading the Way in Pharmaceutical Innovation  ~2 min.

Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....

LLYMarch 19, 2025Eli Lilly and Company LLY Surges After Breakthrough BRAVE-AA-PEDS Study Results  ~2 min.

Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....

LLYMarch 18, 2025Eli Lilly and Company: A Promising Investment in the Pharma Industry  ~1 min.

Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....

LLYMarch 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry  ~2 min.

Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....

LLYMarch 16, 2025Is Eli Lilly and Company LLY Set to Revolutionize the Pharma Industry?  ~2 min.

Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....

LLYMarch 14, 2025Eli Lilly and Company Reports Promising Results in Hair Regrowth Study  ~1 min.

Eli Lilly and Company (LLY) recently announced the positive outcome of their Phase 3 clinical trial for baricitinib, a drug aimed at treating severe alopecia areata in adolescents....

LLYFebruary 28, 2025Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding 50 billion  ~1 min.

Eli Lilly and Company (LLY) is set to significantly increase its manufacturing investment in the United States, surpassing a staggering 50 billion since 2020....

LLYFebruary 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development  ~1 min.

Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....

LLYFebruary 26, 2025ELI LILLY AND COMPANY Launches Additional Zepbound Vial Doses and Offers New Savings  ~2 min.

ELI LILLY AND COMPANY has recently announced the launch of additional Zepbound vial doses, as well as new savings for self-pay patients....

ABTFebruary 20, 2025ABBOTT LABORATORIES Achieves Price Target Forecast with 15.9% Profit  ~1 min.

QuantWave's forecast for ABBOTT LABORATORIES reached its target on February 20, 2025, generating a profit of 15.9%. The forecast signal date was December 10th, 2024, with a price of $114....

SYKSeptember 9, 2024STRYKER CORPORATION Hits Price Target Forecast with 7.09% Profit  ~1 min.

STRYKER CORPORATION has successfully achieved the price target forecast set by QuantWave on June 25, 2024. The stock was signaled for a long position at a price of 335....

AZNAugust 15, 2024Achievement of Price Target Forecast for AstraZeneca PLC Generates Profit of 30.9%  ~1 min.

QuantWave, the automated forecasting platform, successfully predicted a price target for AstraZeneca PLC on October 3, 2023. The forecast indicated a long position with the stock priced at $63.95....

ABTFebruary 22, 2024ABBOTT LABORATORIES Hits Price Target Forecast with 12.4% Profit Gain  ~1 min.

On July 11, 2023, QuantWave's forecast signal for ABBOTT LABORATORIES indicated a long position with a price of $102.83. Fast forward to February 22, 2024, the target price of $115....

ABTOctober 12, 2023ABBOTT LABORATORIES Hits Forecast Price Target with 10.91% Profit, Confirming QuantWave's Accuracy  ~2 min.

Abbott Laboratories (NYSE: ABT) recently achieved the forecast price target set by QuantWave, signaling a profitable short position for investors....